Tuesday tips round-up: Aggreko, Cranswick, GlaxoSmithKline

5th Apr 2011 06:39

Temporary power provider Aggreko's shares rallied yesterday as the market welcomed the news that the company is to supply power to Japan to make up for some of the shortfall from the nuclear plants crippled by the disaster. To be sure, there have been questions from analysts about the impact from the upheavals in the Middle East. But with so many growth opportunities, Aggreko still has plenty of potential headroom, says the Independent, which recommends buying the shares.Food producer Cranswick yesterday issued an update on the final quarter of its financial year, reporting higher volumes, but slower revenue growth. The key talking point, in the Independent's view, was the cautious outlook statement, which sent the shares lower. This is a good company with an affordable stock, but we think investors should remain mindful of the wider economic picture. Hold, the newspaper says.GlaxoSmithKline is a drug maker with a range of consumer health brands, including Panadol, Aquafresh, Contact, Sensodyne, Macleans, Horlicks and Ribena. Glaxo is expanding its market penetration in developing countries, where there is a dividend yield of well over 5%. Buy, says the Scotsman.If you took a straw poll of pollster YouGov's management, they would probably say they were looking to the future with some confidence, especially after yesterday's solid first-half results, showing a 27% in revenues. But problems in Germany and a pretty full valuation of 17 times forward earnings, means that we would hold back from buying just yet, says the Independent, which recommends holding the shares.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.RG